Loading component...
Experience
Stephanie has extensive experience in Medicare Part D financial dynamics and in SAS analyzing patients, drugs, and diseases in Milliman's Consolidated Health Cost Guidelines Sources Dataset (CHSD), IBM MarketScan database, and the Centers for Medicare & Medicaid Services (CMS) 100% Medicare Fee-for-Service (FFS) claims database that contains all Parts A, B, and D claims for Medicare FFS beneficiaries.
Professional Designations
- Stephanie is an associate of the Society of Actuaries (ASA) and a member of the Academy of Actuaries (MAAA)
Education
- Stephanie graduated from the University of Connecticut with a bachelor's degree in Actuarial Science.
Publications
Read their latest work
Article
4 key takeaways from the third round of drugs selected for Medicare drug price negotiation
20 February 2026 - by Maggie Alston, Massey Whorley, Stephanie Leary, Isabelle Creavin
The Centers for Medicare and Medicaid Services announced the list of drugs selected for price negotiation for 2028. We broke down the implications.
Article
Bleeding-related hospitalizations among direct oral anticoagulant users and nonusers in Medicare fee-for-service
22 July 2025 - by Carol Bazell, Maggie Alston, Stephanie Leary, Winston Fopalan, Latha Ganti, Raymond Chang, H. Andrew Wilsey, Christopher Baugh
Among Medicare fee-for-service members, we found the bleeding-related hospitalization rate was four times higher for users of direct oral anticoagulants.
Article
Variation in prevalence and burden of chronic obstructive pulmonary disease by state and insurance type in the United States
26 February 2025 - by Carol Bazell, Maggie Alston, Norbert Feigler, Hayley Germack, Stephanie Leary, Winston Fopalan, David Mannino
Our research on COPD populations shows wide variations in prevalence and burden of disease, depending on the U.S. state and patient insurance type.
Article
Stakeholder perspectives on the transformative IRA Part D benefit redesign
21 December 2023 - by Bruce S. Pyenson, Jennifer Carioto, Michael Rothschild, John Miller, Stephanie Leary
We discuss how the Inflation Reduction Act could affect Medicare Part D plans, members, the government, and pharmaceutical manufacturers.
